Last reviewed · How we verify
Exjade
At a glance
| Generic name | Exjade |
|---|---|
| Also known as | deferasirox oral suspension, Deferasirox, ICL670, DEFERASIROX |
| Sponsor | DisperSol Technologies, LLC |
| Target | Flavin reductase (NADPH), Lysine-specific demethylase 5A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Chronic Iron Overload
- beta Thalassemia
Common side effects
- Diarrhea
- Vomiting
- Nausea
- Abdominal pain
- Skin rashes
- Increases in serum creatinine
- Rash
Serious adverse events
- Drug-induced hepatitis
- Elevations in serum glutamic-pyruvic transaminase (SGPT)/ALT greater than 5 times ULN
- Henoch Schönlein purpura
- Cataract
- Glycosuria/proteinuria
Key clinical trials
- Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.
- Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia (PHASE2)
- Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation (PHASE2)
- Early Screening and Treatment of Heart Complication in Sickle Cell Disease (PHASE2)
- Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia (PHASE3)
- Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
- Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study (NA)
- Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |